ARTICLE | Finance
Stem cells (re)generate rewards for Versant, Bayer
A risky bet on BlueRock’s stem cell technology has paid off for Versant and Bayer
August 9, 2019 8:21 PM UTC
The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock.
Now the partners are reaping the benefits of the $225 million series A with which they launched BlueRock Therapeutics L.P. that year...